

## Resumo das classificações

Proj nº						Mean
1	26	27	20	17	21,5	22,3
2	28	30	18	30	22,5	25,7
3	29	28	28	21	22,5	25,7
4	26	25	24	15	20,0	22,0
5	27	26	25	23	23,0	24,8
6	27	25	24	21	20,5	23,5
7	28	30	28	23	24,5	26,7
8	27	27	21	18	21,5	22,9
9	25	29	30	25	22,5	26,3
10	26	28	19	18	21,5	22,5
11	0	28	25	25	23,0	25,3
12	23	29	24	24	23,5	24,7

The projects must be evaluated according to; 1) State of the art; 2) Project concept;3) Achieved results; 4) Methods; 5) Tasks design; 6) Feasibility and others that will be pertinent for the evaluators.

Each item – scale 1 to 5

SPDM-Proj. 1	<b>Study of Fabry disease-specific cell type through iPSCs differentiation</b>
SPDM-Proj. 2	<b>Integrative approaches to study glutaric acidurias</b>
SPDM-Proj. 3	<b>Application of Whole Exome Sequencing in the research of mitochondrial disorders to clarify unsolved patients with mitochondrial DNA maintenance defects</b>
SPDM-Proj. 4	<b>Application of NGS at the checkpoints of genetic induction and editing of cell models</b>
SPDM-Proj. 5	<b>Assess the effect of Fabry disease severity on iNKT cells frequency, phenotype and function</b>
SPDM-Proj. 6	<b>Proteomic characterization of iPSC models of Gaucher Disease</b>
SPDM-Proj. 7	<b>Genetic substrate reduction therapy for MPS - toward a siRNA-containing nanoparticle targeted to brain cells</b>
SPDM-Proj. 8	<b>The kidney and respiratory chain disorders - a metabolomics approach</b>
SPDM-Proj. 9	<b>Urea cycle disorders and hyperammonemia: enhancing mitochondrial function with translational potential in drug development for rare metabolic diseases</b>
SPDM-Proj. 10	<b>Establishment of na iPSC model for the study of Tay Sachs disease</b>
SPDM-Proj. 11	<b>Towards therapeutic approaches for Human Glycosylation Disorders through immunological characterization</b>
SPDM-Proj. 12	<b>Development of an antisense-mediated exonskipping therapeutic strategy for Mucopolipidosis II: validation at the enzyme level</b>